Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study
- 1 October 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Diseases of the Colon & Rectum
- Vol. 53 (10), 1432-1438
- https://doi.org/10.1007/dcr.0b013e3181e78815
Abstract
Adjuvant therapy results in significant improvement in survival of patients with high-risk colorectal cancer. Little is known about the significance of timing and early discontinuation of adjuvant treatment in such patients. Our study aims to determine the prognostic impact of timing and completion of adjuvant therapy in patients with high-risk colorectal cancer. Medical records of patients with stage III colon and stage II/III rectal cancer diagnosed between 1993 and 2000 in the province of Saskatchewan were reviewed. Cox proportional hazards models were used to analyze the impact of timing and completion of adjuvant therapy on survival. Six hundred sixty-three eligible patients with a median age of 66 years were identified. Sixty-five percent patients received adjuvant <56 days after surgery and 79% patients completed planned treatment. Median follow-up was 54.6 months. Five-year disease-free survival and overall survival of patients who received adjuvant therapy <56 days after surgery was 54.6% and 59.5%, respectively, compared with 51.9% and 57.1%, respectively, of patients who received therapy ≥56 days after surgery (P = NS). The five-year disease disease-free survival and overall survival of patients who completed planned treatment was 56.7% and 62.3%, respectively, compared with 42.1% and 45%, respectively, of patients who required early treatment discontinuation (P < .0001). On multivariate analysis, age ≥65 years, T4 tumor, grade 3 cancer, node-positive disease, rectal tumor, and early treatment discontinuation were identified as poor prognostic factors. Although time to adjuvant therapy following surgical resection did not impact the outcomes, failure to complete planned therapy was associated with adverse prognosis.Keywords
This publication has 23 references indexed in Scilit:
- Lymph Node Evaluation and Survival After Curative Resection of Colon Cancer: Systematic ReviewJNCI Journal of the National Cancer Institute, 2007
- Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patientsBritish Journal of Cancer, 2007
- Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancerCancer, 2006
- Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the ElderlyJournal of Clinical Oncology, 2006
- Completion of Therapy by Medicare Patients With Stage III Colon CancerJNCI Journal of the National Cancer Institute, 2006
- A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancerAnnals of Oncology, 2005
- Mechanisms of oncogenesis in colon versus rectal cancerThe Journal of Pathology, 2001
- Survival of colorectal cancer patients in Europe during the period 1978–1989European Journal of Cancer, 1998
- Prognostic factors in colorectal cancerDiseases of the Colon & Rectum, 1998
- Survival for colon and rectal cancer in a population-based cancer registryEuropean Journal of Cancer, 1996